Analysis of the antitumor activity of gemcitabine and carboplatin against ovarian clear-cell carcinoma using the DNA damage marker γH2AX

Eriko Takatori1
Tadahiro Shoji1
Takashi Sawai2
Akira Kurose3
Toru Sugiyama1

1Department of Obstetrics and Gynecology, Iwate Medical University, Morioka, Japan; 2Department of Pathology, Iwate Medical University, Morioka, Japan; 3Department of Anatomic Pathology, Hirosaki University, Hirosaki, Japan

Background: Differences in the incidence and type of DNA damage induced by antitumor agents for ovarian clear-cell carcinoma (CCC) were determined in two CCC cell lines, using γH2AX.

Materials and methods: The antitumor activity of gemcitabine (GEM) and carboplatin (CBDCA) were examined using cultured cell lines of CCC (OVISE and RMG-I). Each cell line was treated with GEM and CBDCA, the cells were collected, fixed, and then reacted with anti-γH2AX antibody. γH2AX and nuclear DNA were then simultaneously detected by flow cytometry using fluorescein isothiocyanate and propidium iodide, respectively, to determine the amounts of γH2AX formed in each cell-cycle phase.

Results: After administration of GEM, both cell lines showed DNA damage and cell-cycle arrest in the S and G2/M phases, and increased apoptosis. Similarly, with CBDCA, OVISE showed S- and G2/M-phase arrest, while RMG-I showed G2/M-phase arrest.

Conclusion: The mechanism of action of GEM and CBDCA in CCC cell lines was elucidated using γH2AX as a DNA damage marker. Our findings suggested that concomitant use of GEM plus CBDCA may be effective in the treatment of CCC.

Keywords: γH2AX, clear-cell carcinoma, ovarian cancer, DNA damage, apoptosis, gemcitabine, carboplatin

Introduction
Ovarian clear-cell carcinoma (CCC), a subtype of epithelial ovarian cancer, is relatively less sensitive to chemotherapy, and is therefore classified as a refractory ovarian cancer.1 It has been shown that a combination of carboplatin (CBDCA) and paclitaxel (PTX), a standard therapy for ovarian cancer,2,3 is effective against serous adenocarcinoma and endometrioid adenocarcinoma, with a response rate of approximately 75%, while CCC shows lower response rates, ranging from 18% to 50%.4 The incidence of CCC has been increasing and is now estimated to be 23% in Japan, while that in Europe is reported to be 5%–6%. No treatment has been established yet for this histological subtype of ovarian cancer. Histopathology remains the gold standard for classifying epithelial ovarian cancer into subgroups; however, there is emerging evidence indicating differences in the genetic and molecular profiles among these cancers. On the other hand, there is no international consensus regarding the necessity of establishing treatment strategies based on the histological subtype. Current chemotherapeutic options for ovarian cancer include drugs inducing DNA damage (eg, cisplatin and CBDCA), microtubule inhibitors (eg, PTX), topoisomerase inhibitors (eg, polyethylene glycolated liposomal
doxorubicin, topotecan, irinotecan), and antimetabolites (eg, gemcitabine [GEM] and 5-fluorouracil).

Recently, it has become apparent that phosphorylation of histone H2AX, one of the variants of the nucleosome core histone H2A, can serve as a sensitive and reliable marker of DNA damage (Figure 1A). More specifically, DNA damage, particularly that involving the formation of DNA double-strand breaks, induces phosphorylation of histone H2AX on Ser-139; phosphorylated H2AX is termed γH2AX (Figure 1B). Dot γH2AX, detectable using γH2AX-specific antibody, is considered to be a specific marker of DNA damage. Therefore, DNA damage can be detected by immunocytochemistry.

We reported previously that γH2AX is a useful marker for the evaluation of DNA damage and apoptosis. In this study, we focused on γH2AX as a marker of DNA damage to examine the cellular effects of GEM and CBDCA on CCC in terms of cell-cycle arrest, DNA damage, and induction of apoptosis. In addition, chemotherapeutic regimens that are likely to be effective in the treatment of CCC are discussed.

Materials and methods

Cell culture

We used two CCC cell lines (OVISE and RMG-I) obtained from the Health Science Research Resources Bank (Osaka, Japan). OVISE was established from a patient with metastatic disease after completion of six cycles of a platinum-based combination therapy, and was cultured in dishes (BD, Franklin Lakes, NJ, USA) containing Roswell Park Memorial Institute 1640 medium (Sigma-Aldrich, St Louis, MO, USA) supplemented with 10% fetal bovine serum. RMG-I was established from a chemotherapy-naïve patient with ascites, and was reported to show primary platinum resistance. RMG-I was grown in dishes (BD) in Ham F-12 medium supplemented with 10% fetal bovine serum. For both cell lines, the medium was supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin (Meiji Seika, Tokyo, Japan). All cell lines were maintained at 37°C in a humidified atmosphere of 5% CO₂ in air.

Drug

GEM was dissolved in dimethyl sulfoxide (Sigma-Aldrich); the final concentration of dimethyl sulfoxide in the culture medium never exceeded 0.1% (w/v). CBDCA was dissolved in phosphate-buffered saline (PBS). The concentrations of GEM and CBDCA were set to correspond to the blood concentration at a standard clinical dose. Clinical maximum drug concentration and minimum effective concentrations of GEM and CBDCA are 25 µg/mL and 5 ng/mL, and 55 µg/mL and 10 µg/mL, respectively.

Immunohistochemistry

Both the cells floating in the medium and the cells that remained attached after trypsinization were collected and fixed with 1% methanol-free formaldehyde (Polysciences,
Warrington, PA, USA) in PBS at 0°C for 15 minutes and postfixed with 80% ethanol for at least 2 hours at 20°C. The fixed cells were washed twice in PBS and suspended in a 1% (w/v) solution of bovine serum albumin (Sigma-Aldrich) in PBS, to suppress nonspecific antibody binding. The cells were then incubated in 100 µL of 1% bovine serum albumin containing 1:100 diluted antiphosphohistone H2AX (Ser-139) monoclonal antibody (Upstate, Lake Placid, NY, USA) for 2 hours at room temperature, washed twice with PBS, and resuspended in 100 µL of 1:20 diluted fluorescein isothiocyanate-conjugated F(ab')2 fragment of goat antimouse immunoglobulin (Dako, Glostrup, Denmark) for 30 minutes at room temperature in the dark. The cells were then counterstained with 5 µg/mL propidium iodide (Sigma-Aldrich) in the presence of 100 µL of ribonuclease A (Sigma-Aldrich) for 30 minutes.

Fluorescence measurements by flow cytometry
The fluorescein isothiocyanate (green) and propidium iodide (red) fluorescences of individual cells in suspension induced by excitation with a 488 nm argon ion laser were measured using a FACScan flow cytometer (BD). The green and red fluorescences from each cell were separated and quantified using standard optics and CellQuest software (BD). Ten thousand cells were measured per sample. All experiments were repeated at least three times.

After γH2AX and DNA staining, the DNA content and γH2AX content determined by flow cytometry were represented on the x and y axes, respectively. The γH2AX content in each cell cycle was determined, so as to allow examination of the relationships between cell kinetics and the DNA damage induced by antitumor agents.

Results
GEM
In the OVISE cells, treatment with 5 ng/mL or more of GEM mainly caused DNA damage in cells of the early S-phase. After exposure to 100 ng/mL or more of GEM, the S-phase cells showing DNA damage underwent apoptosis. Similarly, in the RMG-I cells, DNA damage was primarily seen in the early S-phase cells following exposure to 5 ng/mL or more of GEM. Treatment with 100 ng/mL or 1 µg/mL GEM induced DNA damage not only in S-phase cells but also in G2/M-phase cells. These cells, however, did not undergo apoptosis (Figure 2A). To investigate the time course of the changes, both cell lines were treated with GEM at the minimum concentration causing DNA damage (5 ng/mL) for different periods of time. In the OVISE cells, DNA damage was mainly confined to S-phase cells after exposure to GEM for 24 hours or more. However, after exposure for 48 hours or more, DNA damage also extended to the cells of the G2/M phase. The S-phase cells with DNA damage underwent apoptosis after exposure to GEM for 48 hours or more, while the number of cells in the G1 phase gradually decreased and there was S-phase arrest. Moreover, G2/M-phase cells showing DNA damage remained viable without undergoing apoptosis. In RMG-I cells, marked DNA damage was observed in the S-phase cells after 24 hours of exposure to GEM, although the cells underwent apoptosis after 72 hours’ exposure to GEM. Similar to the OVISE cells, the gradual decreases in the number of cells in the G1 phase and S-phase arrest were also noted in RMG-I cells. G2/M-phase cells showing DNA damage remained viable without apoptosis even after 120 hours of exposure to GEM, and G2/M-phase arrest was induced (Figure 2B).

CBDCA
DNA damage in the S phase was seen gradually after exposure to CBDCA for 24 hours in the OVISE and RMG-I lines at 1 µg/mL and 10 µg/mL, respectively (Figure 3A). Subsequently, cells with damaged DNA underwent apoptosis. Gradually, both cell lines showed DNA damage in the G2/M phase and underwent apoptosis. OVISE showed S- and G2/M-phase arrest, while RMG-I showed G2/M-phase arrest (Figure 3B).9

Discussion
Numerous distinct dots of γH2AX are usually observed when cells are pretreated with antitumor agents and immunohistochemically stained using γH2AX antibodies. Each of these dots is considered to correspond to a site of DNA damage.6 In apoptotic cells, because of DNA fragmentation, nuclear fragments showing strong staining of γH2AX are commonly observed. Thus, DNA damage and apoptosis can be visualized using γH2AX as an indicator. In a cell, all chromosomal DNA is replicated and the amount of DNA doubles during the S phase; then cell division occurs during the M phase to produce two daughter cells that initiate a new cell cycle. After immunofluorescence staining of γH2AX and counterstaining of DNA, histograms were constructed by plotting the amount of DNA and amount of γH2AX in the cells, determined by flow cytometry, on the x and y axes, respectively, to detect the amount of γH2AX formed in each cell-cycle phase; this allowed a visual estimation of
the extent of DNA damage caused by antitumor agents and examination of changes in the cellular kinetics. In this immunohistochemical γH2AX-detection method, DNA damage can be detected with high sensitivity at much lower concentrations of the necessary agents than in the comet assay, and the extent of DNA damage can be correlated with the phase of the cell cycle.10

Combination chemotherapy with PTX and CBDCA is established as the gold standard for ovarian cancer. This therapy, however, is not sufficiently effective for CCC, and it
Figure 3 (A and B) Bivariate distributions (DNA content vs γH2AX) of OVISE and RMG-I cell lines, treated with carboplatin. The dotted lines indicate control. Arrowheads and arrows indicate DNA damage and apoptosis, respectively. (A) Both cell lines were treated with various concentrations of carboplatin for 24 hours. DNA damage was observed in the S-phase cells at 1 µg/mL and 10 µg/mL concentrations in OVISE and RMG-I, respectively. DNA damage was found in both cell lines at every cell cycle as the concentration increased, and apoptosis occurred at a concentration of 50 µg/mL. More cells remained free of DNA damage in RMG-I than in OVISE. (B) Both cell lines were treated with 1 µg/mL, the minimum concentration inducing DNA damage in either cell line, for various reaction times. In OVISE, S-phase cells with DNA damage progressed to apoptosis after 48 hours. DNA damage was also found in G₂/M-phase cells after 48 hours, but most did not progress to apoptosis. S- and G₂/M-phase arrests were observed. DNA damage was found in S- and G₂/M-phase cells after 48 hours in RMG-I. The S-phase cells with DNA damage progressed to apoptosis 72 hours later, but G₂/M-phase cells showing DNA damage remained. S- and G₂/M-phase arrests were observed.

Abbreviations: DNA, deoxyribonucleic acid; S, synthesis phase; G₁, Gap 1 phase; G₂, Gap 2 phase; M, mitotic phase; h, hours.
has been pointed out that individualization of chemotherapy based on the histological subtypes is needed for this type of cancer. GEM has proved to be effective in patients with ovarian cancer, and a publication-based application of GEM was submitted in September 2010 in Japan. In this study, we attempted to demonstrate the efficacy of GEM and CBDCA, and examine the possibility of expanding the treatment options for patients with CCC, for whom the current treatment options are limited.

GEM is an antimitabolite used to treat recurrent ovarian cancer that is known to exert its antitumor activity via becoming incorporated into the cellular DNA. In both the CCC cell lines used in this study, GEM induced marked DNA damage and cell-cycle arrest in the S phase, probably as a result of the GEM-induced stalled replication forks. However, many cells with DNA damage remained viable even after exposure to GEM for 120 hours, indicating that GEM had only a weak cytocidal effect on the CCC cells.

The results of the study showed that GEM exerted a weaker antitumor effect on the RMG-I cells than on the OVISE cells. Possible reasons for this include the higher percentage of G1/G0 cells and lower percentage of S-phase cells in the RMG-I cell line. A relatively low proportion of cells in the S phase is generally observed in CCCs, and may account for the insufficient antitumor effect of GEM monotherapy in patients with this type of ovarian cancer. Unlike in human myelogenous leukemia cell lines, GEM caused cell-cycle arrest not only in the S phase but also in the G2/M phase in the CCC cell lines. In addition, cells arrested in the G2/M phase of the cell cycle also showed DNA damage. Taking into account the GEM concentrations and the time course of the cellular changes, this may be attributable to the cell-cycle arrest induced at the G2/M checkpoint after progression of the S-phase cells showing DNA damage to the G2 phase. Although the factors involved in the phosphorylation of ataxia telangiectasia and Rad3-related protein after recognition of DNA damage are not yet clearly defined, it is considered that BRCA1, a human tumor-suppressor gene product, may play a role in the process and is responsible for G2/M checkpoint regulation in response to DNA damage. A recent study has shown BRCA1 mutations involved in CCC. Thus, BRCA1 gene mutations in CCC cell lines may be involved in the cell-cycle arrest at the G2/M phase observed in this study.

After CBDCA administration, DNA damage was seen in the S and G2/M phases in both cell lines. OVISE contained a remarkable cell population rescued from apoptosis and surviving with DNA damage. On the other hand, most RMG-I cells with DNA damage underwent apoptosis. These results suggest that cell lines respond differently to platinum agents, ie, RMG-I was cisplatin-resistant but responded to CBDCA.

This study infers that for residual cells in which the cell cycle remains arrested due to DNA damage caused by GEM, effective cytocidal action can theoretically be obtained by additionally or concomitantly administering CBDCA, which exerts effects on any cells in cell-cycle arrest (Table 1). These mechanisms of action for both drugs have already been elucidated in many types of carcinomas other than ovarian CCC. In this paper, the mechanisms of action in CCC are reported. The results obtained suggest that combination therapy with GEM plus CBDCA might be useful in the treatment of CCC. This conclusion was derived from our own study method using flow cytometry with γH2AX as a marker. In order to establish GEM-plus-CBDCA therapy, which is currently being administered in clinical trials, we considered it to be essential to demonstrate its usefulness not only for other types of carcinomas but also for CCC in basic studies. Moreover, another study is currently being conducted to assess whether there are synergistic effects of GEM plus CBDCA.

Currently, a randomized clinical trial (iPLAS) is ongoing as an intergroup study in Japan to compare the efficacy and safety of GEM plus CBDCA with those of polyethylene glycolated liposomal doxorubicin plus CBDCA in patients with platinum-sensitive, recurrent ovarian cancer. Molecular-targeted agents have come to be increasingly used in chemotherapy for ovarian cancer around the world. However, it is still impossible to use such drugs in clinical settings other than physician-initiated clinical trials in Japan. Therefore, effective treatment of CCC needs to be developed using antitumor drugs covered by health insurance. In this study, we used γH2AX as an indicator to examine the antitumor effects of GEM and CBDCA on OVISE and RMG-I cells, and the results suggested that combination chemotherapy with GEM plus CBDCA may be effective for CCC. The method employed in this study is convenient and very

Table 1 Cell kinetics of CCC cells treated with anticancer drugs

<table>
<thead>
<tr>
<th>Drug</th>
<th>DNA damage</th>
<th>Apoptosis</th>
<th>Cell cycle arrest</th>
</tr>
</thead>
<tbody>
<tr>
<td>GEM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OVISE</td>
<td>S</td>
<td>+</td>
<td>S, G2/M</td>
</tr>
<tr>
<td>RMG-I</td>
<td>S, G2/M</td>
<td>+</td>
<td>S, G2/M</td>
</tr>
<tr>
<td>CBDCA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OVISE</td>
<td>S, G2/M</td>
<td>+</td>
<td>S, G2/M</td>
</tr>
<tr>
<td>RMG-I</td>
<td>S, G2/M</td>
<td>+</td>
<td>G2/M</td>
</tr>
</tbody>
</table>

Abbreviations: CCC, clear cell carcinoma; CBDCA, carboplatin; GEM, gemcitabine; S, synthesis phase; G2, Gap 2 phase; M, mitotic phase.
useful to examine the antitumor effects of anticancer drugs, as it takes only a short time for the effects of the agents to be assessed. In this study, we presented the data regarding single-agent administration of GEM and CBDCA. We are currently conducting a study on the combination, and will report the results in a future paper.

This report provides valid findings that would contribute to improvement of the prognosis of patients with CCC. We anticipate that our findings would also promote the development of further in vitro studies.

Disclosure

The authors report no conflicts of interest in this work.

References

10. Watters GP, Smart DJ, Harvey JS, Austin CA. H2AX phosphorylation as a genotoxicity endpoint. Mutat Res. 2009;679:50–58.